Stat News
STAT+: AI drug developer Insilico Medicine and Lilly ink commercialization deal worth up to $2.75 billion
Eli Lilly has struck a commercialization agreement with AI-driven drug developer Insilico Medicine, putting $115 million on the table upfront and up to $2.75 billion in milestone payments. The deal represents one of the larger bets a major pharma company has placed on AI-generated drug candidates. For Insilico, the partnership signals growing industry confidence in its platform's ability to move molecules from algorithm to clinic.
Read article →NPR Health
The CDC doesn't have a director. Can it respond to public health threats?
The CDC currently operates without a confirmed director, raising serious questions about the agency's leadership capacity during potential health crises. Former CDC official Demetre Daskalakis warns that the vacancy creates real vulnerabilities in the government's ability to coordinate and respond to emerging public health threats. The leadership gap comes at a moment when institutional readiness matters most.
Read article →Get this delivered every morning
Join thousands of readers who get the world's most important stories, curated daily.
Start reading free →